Comparison of antitumor activity of a humanized anti-CD40 antibody and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice.

![Graph showing tumor volume comparison](image)

- **Control Ab**
- **hu anti-CD40**
- **Rituxan**

Day 21 Post Treatment

Start on d13

4mg/kg/3 times/wk

(3 doses)
Comparison of antitumor activity of a murine anti-CD40 antibody (SGN-14) and a humanized anti-CD20 antibody against Ramos lymphoma transplanted in SCID mice

Start on d13
4mg/kg/3 times/wk (9 doses)
Antitumor activity of a humanized anti-CD20 antibody and humanized anti-CD40 antibody against IM9, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice

**Fig. 3**

- Control Ab
- Rituxan
- hu Anti-CD40

Survival (total # mice) vs. Days Post Tumor Implant

Start on d3
4mg/kg/3 times/wk (9 doses)
Combination of a humanized anti-CD20 antibody and a murine anti-CD40 antibody (SGN-14) for antitumor activity against H.S. Sultan, (CD20+, CD40+Multiple myeloma) transplanted in SCID mice.

**FIG. 4**

Start on d3
2mg/kg 3 times/wk (9 doses)
Anti-tumor activity of a murine anti-CD40 antibody (SGN-14) and an anti-CD20 antibody (RITUXAN® brand) on RITUXAN® brand resistant Ramos Lymphoma transplanted in SCID mice

![Graph showing tumor volume over days post treatment for control Ab, Rituxan, SGN-14 + Rituxan, and SGN-14.](image)

- **control Ab**
- **Rituxan**
- **SGN-14 + Rituxan**
- **SGN-14**

**Legend:**
- 1/10 (tumor free)
- 10/10 (tumor free)
- Start on d13
- 4mg/kg/3 times/wk (9 doses)